2023
DOI: 10.1111/cen3.12739
|View full text |Cite
|
Sign up to set email alerts
|

The Japanese clinical guidelines 2022 for myasthenia gravis and Lambert–Eaton myasthenic syndrome

Abstract: The revised Japanese clinical guidelines for myasthenia gravis (MG) and Lambert-Eaton myasthenic syndrome (LEMS) were published in 2022. The notable points in these guidelines (GLs) are as follows: (i) these are the first Japanese GLs to include a description of LEMS; (ii) diagnostic criteria of MG are revised to lessen the incidence of false negative patients; (iii) MG is divided into six clinical subtypes; (iv) a high-dose oral steroid regimen with escalation and de-escalation schedule is not recommended by … Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

0
18
0

Year Published

2023
2023
2024
2024

Publication Types

Select...
7

Relationship

2
5

Authors

Journals

citations
Cited by 24 publications
(18 citation statements)
references
References 49 publications
0
18
0
Order By: Relevance
“…The Japanese clinical guidelines 2022 for MG emphasize the importance of achieving MM-5 mg as the treatment goal as soon as practicable, considered equivalent to complete stable remission or pharmacological remission, 5,6,13 whereas patients with MM without a reduced prednisolone dose to 5 mg can still be considered to have good QoL. 27 Molecular targeted drugs, such as C5 inhibitors or FcRn inhibitors, might contribute to achieving treatment goals by rapidly improving signs and symptoms of gMG and, in turn, QoL.…”
Section: Discussionmentioning
confidence: 99%
See 2 more Smart Citations
“…The Japanese clinical guidelines 2022 for MG emphasize the importance of achieving MM-5 mg as the treatment goal as soon as practicable, considered equivalent to complete stable remission or pharmacological remission, 5,6,13 whereas patients with MM without a reduced prednisolone dose to 5 mg can still be considered to have good QoL. 27 Molecular targeted drugs, such as C5 inhibitors or FcRn inhibitors, might contribute to achieving treatment goals by rapidly improving signs and symptoms of gMG and, in turn, QoL.…”
Section: Discussionmentioning
confidence: 99%
“…4 The Japanese clinical guidelines 2022 for myasthenia gravis state that the treatment goal should be rapid achievement of minimal manifestations with oral prednisolone of 5 mg/day or below (MM-5 mg), where minimal manifestations (MM) is defined as no symptoms or functional limitations from MG, with or without weakness on examination of some muscles. 5,6 The first line of treatment includes low-dose prednisolone (≤10 mg/day, not to exceed ≥20 mg/day) with a calcineurin inhibitor (e.g. tacrolimus, cyclosporine) and an acetylcholinesterase inhibitor (AChEI).…”
Section: Introductionmentioning
confidence: 99%
See 1 more Smart Citation
“…for MG/Lambert-Eaton myasthenic syndrome. 3 In these guidelines, diagnostic criteria of MG were revised, and six clinical subtypes were clarified. It was also mentioned that a high-dose oral steroid regimen with escalation and de-escalation schedule is not recommended.…”
Section: Murai Et Al Introduced Newly Published Japanese Clinical Gui...mentioning
confidence: 99%
“…Murai et al . introduced newly published Japanese clinical guidelines for MG/Lambert–Eaton myasthenic syndrome 3 . In these guidelines, diagnostic criteria of MG were revised, and six clinical subtypes were clarified.…”
mentioning
confidence: 99%